Florian Thieben, M.Sc.

Universitätsklinikum Hamburg-Eppendorf (UKE)
Sektion für Biomedizinische Bildgebung
Lottestraße 55
2ter Stock, Raum 202
22529 Hamburg
- Postanschrift -

Technische Universität Hamburg (TUHH)
Institut für Biomedizinische Bildgebung
Gebäude E, Raum 4.044
Am Schwarzenberg-Campus 3
21073 Hamburg

Tel.: 040 / 7410 56355
E-Mail: f.thieben(at)uke.de
E-Mail: florian.thieben(at)tuhh.de
ORCID: https://orcid.org/0000-0002-2890-5288

Research Interests

  • Magnetic Particle Imaging
  • Low noise electronics
  • Inductive sensors and filters
  • Magnetic Particle Imaging scanner characterization

Curriculum Vitae

Florian Thieben works as an electrical engineer in the group of Tobias Knopp for experimental Biomedical Imaging at the University Medical Center Hamburg-Eppendorf and the Hamburg University of Technology. In 2017 he graduated with a master's degree thesis on Entwicklung eines kompakten Magnet Partikel Spektrometers mit gradiometrischer Empfangskette".

Journal Publications

[180976]
Title: MPI Signal Performance of Resotran.
Written by: K. Scheffler, F. Thieben, F. Mohn, M. Graeser, and T. Knopp
in: <em>12th International Workshop on Magnetic Particle Imaging (IWMPI 2023)</em>. (2023).
Volume: Number:
on pages: 1-1
Chapter:
Editor:
Publisher:
Series:
Address:
Edition:
ISBN:
how published:
Organization:
School:
Institution:
Type:
DOI:
URL: https://journal.iwmpi.org/index.php/iwmpi/article/view/584
ARXIVID:
PMID:

[www]

Note: inproceedings

Abstract: An important ingredient for clinical translation of Magnetic Particle Imaging (MPI) is the availability of superparamagnetic iron-oxid nanoparticles (SPIOs) with given medical approval for human interventions. Many SPIOs used as tracer-material in magnetic resonance imaging (MRI), do not have the magnetic properties needed for a potent signal generation in MPI. In particular they are often too small and thus the thermal energy dominates the magnetic energy leading to a linear magnetization behavior, which is not suitable for signal generation and spatial encoding in MPI. Some particle types are too large and block the Neél relaxation process due to strong magnetic anisotropies, reducing their ability to follow the field at excitation frequencies between 10 kHz to 150 kHz. At the same time, the medical approval of dedicated MPI tracers with optimal signal performance is very costly and tedious and will only turn profitable for companies with a clear clinical business case. Fortunately, there are some tracers that are suitable for both MRI and MPI and thus evaluating newly introduced MRI tracers is essential for potential human MPI studies. We show that the new MRI contrast agent Resotran (b.e.imaging GmbH, Baden-Baden, Germany, medically approved in 10/2022 under reg. no. 7002837.00.00 in Germany) is suitable for MPI. Initial Magnetic Particle Spectroscopy measurements indicate that Resotran shows a similar performance as the formerly approved tracer Resovist (Bayer Schering Pharma, Berlin, Germany) and the pre-clinical MPI tracer perimag (micromod Partikeltechnologie, Rostock, Germany). In combination with human-sized MPI systems, this paves the way towards first human MPI experiments.

Conference Proceedings

[180976]
Title: MPI Signal Performance of Resotran.
Written by: K. Scheffler, F. Thieben, F. Mohn, M. Graeser, and T. Knopp
in: <em>12th International Workshop on Magnetic Particle Imaging (IWMPI 2023)</em>. (2023).
Volume: Number:
on pages: 1-1
Chapter:
Editor:
Publisher:
Series:
Address:
Edition:
ISBN:
how published:
Organization:
School:
Institution:
Type:
DOI:
URL: https://journal.iwmpi.org/index.php/iwmpi/article/view/584
ARXIVID:
PMID:

[www] [BibTex]

Note: inproceedings

Abstract: An important ingredient for clinical translation of Magnetic Particle Imaging (MPI) is the availability of superparamagnetic iron-oxid nanoparticles (SPIOs) with given medical approval for human interventions. Many SPIOs used as tracer-material in magnetic resonance imaging (MRI), do not have the magnetic properties needed for a potent signal generation in MPI. In particular they are often too small and thus the thermal energy dominates the magnetic energy leading to a linear magnetization behavior, which is not suitable for signal generation and spatial encoding in MPI. Some particle types are too large and block the Neél relaxation process due to strong magnetic anisotropies, reducing their ability to follow the field at excitation frequencies between 10 kHz to 150 kHz. At the same time, the medical approval of dedicated MPI tracers with optimal signal performance is very costly and tedious and will only turn profitable for companies with a clear clinical business case. Fortunately, there are some tracers that are suitable for both MRI and MPI and thus evaluating newly introduced MRI tracers is essential for potential human MPI studies. We show that the new MRI contrast agent Resotran (b.e.imaging GmbH, Baden-Baden, Germany, medically approved in 10/2022 under reg. no. 7002837.00.00 in Germany) is suitable for MPI. Initial Magnetic Particle Spectroscopy measurements indicate that Resotran shows a similar performance as the formerly approved tracer Resovist (Bayer Schering Pharma, Berlin, Germany) and the pre-clinical MPI tracer perimag (micromod Partikeltechnologie, Rostock, Germany). In combination with human-sized MPI systems, this paves the way towards first human MPI experiments.